Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM97IN2)

Drug Name
Paltusotine Drug Info
Synonyms
Paltusotine; 2172870-89-0; Paltusotine [INN]; F2IBD1GMD3; CRN00808; CRN-00808; 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl]-2-hydroxybenzonitrile; 3-(4-(4-Aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl)-2-hydroxybenzonitrile; Benzonitrile, 3-(4-(4-amino-1-piperidinyl)-3-(3,5-difluorophenyl)-6-quinolinyl)-2-hydroxy-; Benzonitrile, 3-[4-(4-amino-1-piperidinyl)-3-(3,5-difluorophenyl)-6-quinolinyl]-2-hydroxy-; UNII-F2IBD1GMD3; PALTUSOTINE [USAN]; SCHEMBL19769109; BDBM405588; GLXC-26596; PALTUSOTINE (CRN00808); US10351547, Compound 2-2; AKOS040759931; AT37182; MS-28323; HY-109155; CS-0116068; 3-[4-(4-Amino-1-piperidinyl)-3-(3,5-difluorophenyl)-6-quinolinyl]-2-hydroxybenzonitrile; IUD
Indication
Disease Entry ICD 11 Status REF
Acromegaly 5A60.0 Phase 3 [1]
Cross-matching ID
PubChem CID
134168328
TTD Drug ID
DM97IN2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Somatostatin receptor type 2 (SSTR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pasireotide DMHM7JS Cushing disease 5A70 Approved [3]
Octreotide DMHIDCJ Acromegaly 5A60.0 Approved [4]
Lanreotide acetate DMG6ZU4 Acromegaly 5A60.0 Approved [5]
Ga-68-DOTATOC DMZ0P95 Diagnostic imaging N.A. Approved [6]
Copper dotatate Cu-64 DM26KR1 Diagnostic imaging N.A. Approved [7]
ODT-8 DMBWO5T N. A. N. A. Phase 3 [8]
TBR-760 DMM5BVG Pituitary adenoma 2F37.0 Phase 2 [9]
Re-188-P-2045 DM614BA Lung cancer 2C25.0 Phase 1/2 [10]
PEN-221 DMMAUOK Neuroendocrine cancer 2B72.1 Phase 1/2 [11]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatostatin receptor type 2 (SSTR2) TTZ6T9E SSR2_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT04837040) A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (PATHFNDR-1). U.S.National Institutes of Health.
2 Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022 Apr;25(2):328-339.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
4 Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
5 Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8 Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
9 TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
10 The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.